The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
Working with clinical decision support vendor ActX, the suburban Chicago health system has seen strong demand for PGx and genetically informed preventive care.
The company expects to garner clearance for its platform in the US first for Lynch syndrome as it builds additional evidence for an immunotherapy application.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
In an interview, Marilyn Li and Douglas Stewart discuss why ACMG has put forth points that doctors and labs should consider when presumed germline findings crop up in tumor testing.
A pilot project showed that clinics using the InheRET tool were able to gather more complete family history information from patients, which is important for further cancer risk evaluation.
Data presented at ACMG's online annual meeting suggests that more than 10 percent of prostate cancer patients across disease stages carry inherited cancer-related variants.
